Dronedarone HCL

Dronedarone HCL

350 USD ($)/Kilograms

Product Details:

  • Shelf Life 3 Years
  • Molecular Formula C31H44N2O5S
  • Taste Other
  • Molecular Weight 556.8 Kilograms (kg)
  • Storage Dry Place
  • Smell Other
  • HS Code 29350090
  • Click to view more

Price And Quantity

  • 100kg Kilograms
  • 350 USD ($)/Kilograms

Product Specifications

  • 556.8 Kilograms (kg)
  • Dry Place
  • Medicine Grade
  • Other
  • 29350090
  • Antipyretic Analgesics and NSAIDs
  • C31H44N2O5S
  • Other
  • Powder
  • Dronedarone is a member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias
  • 99
  • 141626-36-0
  • 3 Years
  • Dronedarone

Trade Information

  • Cash Advance (CA), Cash in Advance (CID), Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C)
  • 2 Week
  • Yes
  • Free samples are available
  • HDPE drums
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Product Description

Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting -adrenergic receptors. Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone
Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'APIs' category

We are exporting in the countries such as Afghanistan, Algeria, Argentina, Bolivia, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Indonesia, Iran, Jordan, Morocco, Panama, South Korea, Taiwan, Turkey, Uruguay, Vietnam and Yemen.
INDO PHARM All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.